GOSSAMER BIO, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
GOSSAMER BIO, INC. (GOSS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$138.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-17
- GOSSAMER BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$138.05M.
- GOSSAMER BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$32.18M.
- GOSSAMER BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$134.07M.
- GOSSAMER BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$175.78M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$138.05M 10-K · filed 2026-03-17 | |
| 2024-12-31 | -$32.18M 10-K · filed 2026-03-17 | |
| 2023-12-31 | -$134.07M 10-K · filed 2026-03-17 | |
| 2022-12-31 | -$175.78M 10-K · filed 2025-03-13 | |
| 2021-12-31 | -$183.19M 10-K · filed 2024-03-05 | |
| 2020-12-31 | -$186.89M 10-K · filed 2023-03-17 | |
| 2019-12-31 | -$138.34M 10-K · filed 2022-03-03 | $138.34M 10-K · filed 2020-03-24 |
| 2018-12-31 | -$116.92M 10-K · filed 2021-02-26 | $116.92M 10-K · filed 2020-03-24 |
| 2017-12-31 | $6.77M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |